Nucleic acid encoding receptor type protein kinase

Abstract

To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection.

1 - 3 . (canceled)  
     
     
         4 . A nucleic acid encoding a polypeptide having a receptor protein kinase activity, wherein said nucleic acid has length mutation in a nucleotide sequence of a juxtamembrane.  
     
     
         5 . The nucleic acid according to  claim 4 , wherein said length mutation is tandem duplication mutation.  
     
     
         6 . The nucleic acid according to  claim 4 , wherein said receptor protein kinase is a receptor tyrosine kinase.  
     
     
         7 . The nucleic acid according to  claim 6 , wherein said receptor tyrosine kinase is FMS-like tyrosine kinase 3 (FLT3).  
     
     
         8 . A tandem duplication mutant polypeptide encoded by the nucleic acid of  claim 4 .  
     
     
         9 . A cell expressing the nucleic acid according to  claim 4  or the polypeptide according to  claim 8 .  
     
     
         10 . A nucleic acid fragment of the nucleic acid of  claim 4 , wherein said fragment has tandem duplication mutation in a nucleotide sequence of a juxtamembrane.  
     
     
         11 . A method for screening a drug for examination and treatment of a blood cell disease or a hematopoietic stem cell disease, comprising subjecting a candidate compound to a screening system using a hematopoietic stem cell expressing a nucleic acid encoding a tandem duplication mutant polypeptide and a cell expressing the normal FLT3.  
     
     
         12 . The method according to  claim 11 , wherein said nucleic acid has a tandem duplication mutation in a nucleotide sequence of a juxtamembrane.  
     
     
         13 . A method for screening a drug for examination and treatment of a blood cell disease or a hematopoietic stem cell disease, comprising subjecting a candidate compound to a screening system using a hematopoietic stem cell expressing the nucleic acid according to  claim 4  or the polypeptide according to  claim 8  and a cell expressing the normal FLT3.  
     
     
         14 . A method for regulating proliferation, immune response or signal information transmission of a blood cell or a hematopoietic stem call, comprising administering the nucleic acid of  claim 4  to an individual.  
     
     
         15 . A method for pathologic judgment of myelodysplastic syndrome (MDS) or leukemia, comprising detecting the nucleic acid of  claim 4  or the nucleic acid fragment of  claim 10  as a marker for myelodysplastic syndrome (MDS) or leukemia.  
     
     
         16 . A method for pathologic judgment of myelodysplastic syndrome (MDS) or leukemia, comprising detecting the tandem duplication mutant polypeptide of  claim 8  as a marker for myelodysplastic syndrome (MDS) or leukemia.